September 5, 2019 / 11:44 AM / 3 months ago

BRIEF-IFM Therapeutics Announces Collaboration and Exclusive Option Agreement for cGAS/STING-Focused Subsidiary, IFM Due

Sept 5 (Reuters) - Novartis AG:

* IFM THERAPEUTICS ANNOUNCES COLLABORATION AND EXCLUSIVE OPTION AGREEMENT FOR CGAS/STING-FOCUSED SUBSIDIARY, IFM DUE

* IFM THERAPEUTICS SAYS UNIT REACHED A COLLABORATION AND EXCLUSIVE OPTION AGREEMENT WITH NOVARTIS

* IFM THERAPEUTICS SAYS TO DEVELOP SUITE OF IMMUNOTHERAPIES INHIBITING CGAS/STING PATHWAY TO TREAT A RANGE OF SERIOUS INFLAMMATORY & AUTOIMMUNE DISEASES

* IFM THERAPEUTICS SAYS NOVARTIS WILL MAKE FIXED PAYMENTS SUFFICIENT TO FULLY FINANCE IFM DUE’S RESEARCH & DEVELOPMENT COSTS FOR CGAS/STING PROGRAM

* IFM THERAPEUTICS SAYS OPTION EXERCISE, IFM DUE’S SHAREHOLDERS WILL BE ENTITLED TO CONSIDERATION IN AGGREGATE VALUE OF UP TO $840 MILLION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below